{"id":"red-blood-cells","_fda":{"id":"38f35892-fad5-8465-e063-6294a90a32a4","set_id":"9f999b75-8a66-40bf-9352-478850b41225","openfda":{"spl_id":["38f35892-fad5-8465-e063-6294a90a32a4"],"brand_name":["Ultratag RBC"],"spl_set_id":["9f999b75-8a66-40bf-9352-478850b41225"],"package_ndc":["69945-068-10","69945-068-20"],"product_ndc":["69945-068"],"generic_name":["KIT FOR THE PREPARATION OF TECHNETIUM TC 99M RED BLOOD CELLS"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Curium US LLC"],"application_number":["NDA019981"],"is_original_packager":[true]},"version":"17","warnings":["WARNINGS None known."],"pregnancy":["Pregnancy Animal reproduction studies have not been conducted with technetium Tc 99m red blood cells. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Technetium Tc 99m red blood cells should be administered to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses."],"description":["DESCRIPTION Ultratag ™ RBC (Kit for the Preparation of Technetium Tc 99m Red Blood Cells Injection) is a sterile, nonpyrogenic, diagnostic kit for the in vitro preparation of Technetium Tc 99m Red Blood Cells Injection. Each kit consists of three separate nonradioactive components: 1. A 10 milliliter reaction vial containing: Stannous Chloride, Dihydrate (SnCl 2 •2H 2 O) – 50 mcg minimum Stannous Chloride, Dihydrate (SnCl 2 •2H 2 O) – 96 mcg theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl 2 •2H 2 O) – 105 mcg maximum Sodium Citrate, Dihydrate – 3.67 mg Dextrose, Anhydrous – 5.5 mg Hydrochloric Acid – 0.47 mg Prior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon. 2. Syringe I contains: Sodium Hypochlorite – 0.6 mg in Sterile Water for Injection The total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite. 3. Syringe II contains: Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mg Dextrose, Anhydrous – 12 mg in Sterile Water for Injection The total volume of this syringe is 1 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid as needed."],"precautions":["PRECAUTIONS General The components of the kit are sterile and nonpyrogenic. It is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation. The contents of the kit are intended only for use in the preparation of technetium Tc 99m red blood cells and are NOT to be administered directly to the patient. The contents of this kit are not radioactive. After sodium pertechnetate Tc 99m is added, however, adequate shielding of the final preparation must be maintained. Technetium Tc 99m red blood cells must be handled with care to ensure minimum radiation exposure to the patient, consistent with proper patient management, and to ensure minimum radiation exposure to occupational workers. The labeled red blood cells must be reinjected only into the patient from whom the blood was drawn. Nuclear medicine procedures involving withdrawal and reinjection of blood have the potential for transmission of blood borne pathogens. Procedures should be implemented to avoid administration errors and viral contamination of personnel during blood product labeling. A system of checks similar to the ones used for administering blood transfusions should be routine. Clinical trials were conducted with a variety of prescription and nonprescription medications and showed no significant effect on the in vitro labeling efficiency of Ultratag ™ RBC. Unlike stannous pyrophosphate red blood cell kits, heparinized patients (11) showed minimal interference with Ultratag™ RBC labeling efficiency (95% with heparin, 97% without heparin). It is recommended that the labeled red blood cells be administered within 30 minutes of preparation or as soon as possible thereafter. A small study showed that technetium Tc 99m red blood cells prepared with Ultratag™ RBC have equivalent in vivo labeling efficiency when administered both immediately after preparation (5 patients studied) and at 6 hours after preparation (6 patients studied) with a 24-hour labeling efficiency averaging 97% for both groups. Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides. Carcinogenesis, Mutagenesis, Impairment of Fertility No long term animal studies have been performed to evaluate carcinogenic or mutagenic potential or to determine the effects on male or female fertility. Pregnancy Animal reproduction studies have not been conducted with technetium Tc 99m red blood cells. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Technetium Tc 99m red blood cells should be administered to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses. Nursing Mothers Technetium Tc 99m is excreted in human milk during lactation. Therefore, formula feedings should be substituted for breast feeding. Pediatric Use Safety and efficacy in pediatric patients have not been established."],"how_supplied":["HOW SUPPLIED Catalog Number 068. Ultratag™ RBC consists of three separate nonradioactive components: 1. A 10 milliliter reaction vial containing: Stannous Chloride, Dihydrate (SnCl 2 •2H 2 O) – 50 mcg minimum Stannous Chloride, Dihydrate (SnCl 2 •2H 2 O) – 96 mcg theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl 2 •2H 2 O) – 105 mcg maximum Sodium Citrate, Dihydrate – 3.67 mg Dextrose, Anhydrous – 5.5 mg Hydrochloric Acid – 0.47 mg Prior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon. 2. Syringe I contains: Sodium Hypochlorite – 0.6 mg in Sterile Water for Injection The total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite. 3. Syringe II contains: Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mg Dextrose, Anhydrous – 12 mg in Sterile Water for Injection The total volume of this syringe is 1 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid as needed. Storage The kit should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Syringe I should be protected from light if not stored in the kit tray."],"pediatric_use":["Pediatric Use Safety and efficacy in pediatric patients have not been established."],"effective_time":"20250702","nursing_mothers":["Nursing Mothers Technetium Tc 99m is excreted in human milk during lactation. Therefore, formula feedings should be substituted for breast feeding."],"adverse_reactions":["ADVERSE REACTIONS None known."],"contraindications":["CONTRAINDICATIONS None known."],"general_precautions":["General The components of the kit are sterile and nonpyrogenic. It is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation. The contents of the kit are intended only for use in the preparation of technetium Tc 99m red blood cells and are NOT to be administered directly to the patient. The contents of this kit are not radioactive. After sodium pertechnetate Tc 99m is added, however, adequate shielding of the final preparation must be maintained. Technetium Tc 99m red blood cells must be handled with care to ensure minimum radiation exposure to the patient, consistent with proper patient management, and to ensure minimum radiation exposure to occupational workers. The labeled red blood cells must be reinjected only into the patient from whom the blood was drawn. Nuclear medicine procedures involving withdrawal and reinjection of blood have the potential for transmission of blood borne pathogens. Procedures should be implemented to avoid administration errors and viral contamination of personnel during blood product labeling. A system of checks similar to the ones used for administering blood transfusions should be routine. Clinical trials were conducted with a variety of prescription and nonprescription medications and showed no significant effect on the in vitro labeling efficiency of Ultratag ™ RBC. Unlike stannous pyrophosphate red blood cell kits, heparinized patients (11) showed minimal interference with Ultratag™ RBC labeling efficiency (95% with heparin, 97% without heparin). It is recommended that the labeled red blood cells be administered within 30 minutes of preparation or as soon as possible thereafter. A small study showed that technetium Tc 99m red blood cells prepared with Ultratag™ RBC have equivalent in vivo labeling efficiency when administered both immediately after preparation (5 patients studied) and at 6 hours after preparation (6 patients studied) with a 24-hour labeling efficiency averaging 97% for both groups. Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides."],"instructions_for_use":["Instructions for the Preparation of Technetium Tc 99m Red Blood Cells Injection Using Ultrat ag TM RBC 1. Collect patient's blood sample (1.0 to 3.0 mL) using heparin or ACD as an anticoagulant. The amount of ACD should not exceed 0.15 mL of ACD per mL of blood. The recommended amount of heparin is 10-15 units per mL of blood. DO NOT USE EDTA OR OXALATE AS AN ANTICOAGULANT. 2. Using a large-bore (19 to 21 gauge) needle, transfer 1.0 to 3.0 mL of anticoagulated whole blood to the reaction vial and gently mix to dissolve the lyophilized material. Allow to react for five minutes. 3. Add contents of Syringe I, mix by gently inverting four to five times. 4. Add the contents of Syringe II to the reaction vial. Mix by gently inverting four to five times. 5. Place the vial in a lead shield fitted with a lead cap and having a minimum wall thickness of 1/8 inch. Add 370 to 3700 MBq (10 to 100 mCi) sodium pertechnetate Tc 99m (in a volume of up to 3 mL) to the reaction vial. The avoidance of long technetium Tc 99 in-growth times and the use of fresh sodium pertechnetate Tc 99m generator eluate is recommended. 6. Mix by gently inverting reaction vial four to five times. Allow to react for 20 minutes with occasional mixing. 7. Technetium Tc 99m red blood cells should be injected within 30 minutes of preparation or as soon as possible thereafter. 8. If desired, assay labeling efficiency immediately prior to injection. Typical labeling efficiency is greater than 95%. 9. Mix gently prior to withdrawal of patient dose. Aseptically transfer the technetium Tc 99m red blood cells to a syringe for administration to the patient. Use largest bore needle compatible with patient administration to prevent hemolysis. 10. Assay the Tc 99m red blood cell patient dose in a suitable calibrator and complete the radioassay information label. Affix the radioassay information label to the shield. NOTES 1. The kit does not contain an anticoagulant. Therefore, a syringe treated with ACD or heparin must be used for drawing the patient's blood. The amount of ACD should not exceed 0.15 mL of ACD per mL of blood. The recommended amount of heparin is 10-15 units per mL of blood. Improperly anticoagulated blood will be unsuitable for reinjection. 2. If desired, the labeling yield determination can be carried out as follows: Transfer 0.2 mL of the technetium Tc 99m red blood cells to a centrifuge tube containing 2 mL of 0.9% NaCl. Centrifuge for five minutes and carefully pipet off the diluted plasma. Measure the radioactivity in the plasma and red blood cells separately in a suitable counter. Calculate labeling efficiency as follows: This reagent kit is approved for distribution to persons licensed by the U.S. Nuclear Regulatory Commission to use byproduct material identified in Section 10 CFR 35.200 or under an equivalent license of an Agreement state. ©2025 Curium US LLC. Ultratag TM RBC, Curium TM , and the Curium logo are trademarks of a Curium company. Manufactured by: Curium US LLC Maryland Heights, MO 63043 Made in USA A068I0 R06/2025 CURIUM TM image description"],"storage_and_handling":["Storage The kit should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Syringe I should be protected from light if not stored in the kit tray."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY In vitro Tc 99m red blood cell labeling is accomplished by adding 1.0 to 3.0 milliliters of autologous whole blood, anticoagulated with heparin or Anticoagulant Citrate Dextrose Solution (ACD), to the reaction vial. A portion of the stannous ion in the reaction vial diffuses across the red blood cell membrane and accumulates intracellularly. The in vitro Tc 99m red blood cell labeling efficiency can decrease in the presence of excess ACD. Excess ACD apparently impairs the diffusion of stannous ion across the red blood cell membrane. Therefore, the ACD concentration used for blood collection should not exceed 0.15 mL ACD per mL of blood. Sodium hypochlorite is then added to the reaction vial to oxidize the extracellular stannous ion. Since the hypochlorite does not cross the red blood cell membrane, the oxidation of stannous ion is selective for the extracellular tin. A citric acid, sodium citrate and dextrose solution is then added to the reaction vial to sequester any residual extracellular stannous ion, rendering it more readily available for oxidation by sodium hypochlorite. Radioactive labeling of the red blood cells is completed by addition of sodium pertechnetate Tc 99m to the oxidized reaction vial. The pertechnetate Tc 99m diffuses across the red blood cell membrane and is reduced by the intracellular stannous ion. The reduced technetium Tc 99m cannot diffuse out of the red blood cell. The red blood cell labeling is essentially complete within 20 minutes of sodium pertechnetate Tc 99m addition to the reaction vial. Red blood cell labeling efficiency of ≥95% is typically obtained using this in vitro labeling procedure. In vitro Tc 99m red blood cell labeling efficiency can decrease when excessive amounts of Tc 99 are allowed to accumulate in the sodium pertechnetate Tc 99m generator eluate; in this situation, efficiency decreases even further if excess (i.e. >0.15 mL per mL of blood) ACD buffer is used. Therefore, long Tc 99 in-growth times are to be avoided; the use of fresh (≤24 hour in-growth time) sodium pertechnetate Tc 99m generator eluate is recommended. After the labeling procedure is completed, the technetium Tc 99m red blood cells are then reinjected intravenously into the patient for gamma scintigraphic imaging. Following intravenous injection, the technetium Tc 99m red blood cells distribute within the blood pool with an estimated volume of distribution of approximately 5.6% of bodyweight. The technetium Tc 99m is well retained in the blood pool with an estimated biological half-life of approximately 29 hours. Of the total technetium Tc 99m retained in the whole blood pool 24 hours after administration, 95% remains bound to the red blood cells. Approximately 25% of the injected dose is excreted in the urine in the first 24 hours."],"indications_and_usage":["INDICATIONS AND USAGE Technetium Tc 99m red blood cells are used for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding."],"spl_unclassified_section":["Rx o nly Diagnostic–For Intravenous Use","PHYSICAL CHARACTERISTICS Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. 1 The principal photon that is useful for detection and imaging is listed in Table 1. Table 1. Principal Radiation Emission Data 1 Radiation Mean % / Disintegration Energy (keV) Gamma-2 89.07 140.5 The specific gamma ray constant for technetium Tc 99m is 0.78 R/mCi-hr at 1 cm. The first half-value thickness of lead (Pb) for technetium Tc 99m is 0.017 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide resulting from the interposition of various thicknesses of lead (Pb) is presented in Table 2. For example, the use of 0.25 cm of lead will decrease the external radiation exposure by a factor of about 1000. Table 2. Radiation Attenuation by Lead Shielding Shield Thickness (Pb) cm Coefficient of Attenuation 0.017 0.5 0.08 10 -1 0.16 10 -2 0.25 10 -3 0.33 10 -4 To correct for physical decay of this radionuclide, the fractions that remain at selected intervals after the time of calibration are presented in Table 3. 1 Kocher, David C., \"Radioactive Decay Tables,\" DOE/TIC 11026, 108 (1981). Table 3. Physical Decay Chart: Technetium Tc 99m , Half-Life : 6.02 Hours Hours Fraction Remaining Hours Fraction Remaining 0* 1.000 7 0.447 1 0.891 8 0.398 2 0.794 9 0.355 3 0.708 10 0.316 4 0.631 11 0.282 5 0.562 12 0.251 6 0.501 *Calibration Time","RADIATION DOSIMETRY The estimated radiation doses to an average adult (70 Kg) from an intravenous injection of a maximum dose of 740 MBq (20 mCi) of technetium Tc 99m red blood cells are shown in Table 4. These radiation absorbed dose values were calculated using the Medical Internal Radiation Dose (MIRD) Committee Schema. Table 4. Absorbed Radiation Dose Estimates 2 For Ultrat ag ™ RBC Technetium Tc 99m Red Blood Cells Injection* Organ mGy/740 MBq rads/20 mCi Total Body 3.0 0.30 Spleen 22 2.2 Bladder Wall 4.8 0.48 Testes 2.2 0.22 Ovaries 3.2 0.32 Blood 8.0 0.80 Red Marrow 3.0 0.30 Heart Wall 20 2.0 Liver 5.8 0.58 Bone Surfaces 4.8 0.48 * Assumes non-resting state and biological half-life for all organs and whole body of 63.7 hours. The peak percent dose for heart chambers is 15.5%, for liver is 5.57%, spleen is 4.07% and for remainder of body is 74.8%. Assumes patient voids at 2.0 hour intervals. 2 Dose estimates based on Phase I human biodistribution data generated at Brookhaven National Laboratories. Dose estimates were calculated at Oak Ridge Associated Universities, Oak Ridge, Tennessee."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The Instructions for Preparation must be carefully followed for preparing technetium Tc 99m red blood cells using Ultratag™ RBC. The suggested dose range of technetium Tc 99m red blood cells in the average patient (70 kg) is 370 MBq (10 mCi) to 740 MBq (20 mCi). The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Aseptic procedures and a shielded syringe should be employed in preparing and withdrawing doses for administration to patients. The user should wear waterproof gloves during the administration procedure."],"spl_product_data_elements":["Ultratag RBC Kit for the Preparation of Technetium Tc 99m Red Blood Cells RBC REACTION VIAL rbc reaction vial ANHYDROUS DEXTROSE TRISODIUM CITRATE DIHYDRATE SODIUM HYDROXIDE STANNOUS CHLORIDE STANNOUS CATION SODIUM HYPOCHLORITE Sodium Hypochlorite SODIUM HYPOCHLORITE WATER SODIUM HYDROXIDE ACD ACD CITRIC ACID MONOHYDRATE TRISODIUM CITRATE DIHYDRATE WATER ANHYDROUS DEXTROSE"],"spl_unclassified_section_table":["
RadiationMean % / Disintegration Energy (keV)
Gamma-289.07140.5
","
Shield Thickness (Pb) cm Coefficient of Attenuation
0.0170.5
0.0810 -1
0.1610 -2
0.2510 -3
0.3310 -4
","
HoursFraction Remaining HoursFraction Remaining
0*1.00070.447
10.89180.398
20.79490.355
30.708100.316
40.631110.282
50.562120.251
60.501
","
OrganmGy/740 MBqrads/20 mCi
Total Body3.00.30
Spleen222.2
Bladder Wall4.80.48
Testes2.20.22
Ovaries3.20.32
Blood8.00.80
Red Marrow3.00.30
Heart Wall202.0
Liver5.80.58
Bone Surfaces4.80.48
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL 69945-068-10 Ultratag™ RBC (Kit for the Preparation of Technetium Tc 99m Red Blood Cells Injection) Sterile, non-pyrogenic. For intravenous use after drug preparation. Single-Dose Vial. Discard unused portion. See package insert for directions for use. Do not use sodium pertechnetate Tc 99m solutions containing an oxidizing agent. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from light. Rx only LOT EXP. EACH KIT CONTAINS: 1 10 mL reaction vial containing stannous chloride, dihydrate (SnCl 2•2H 2 0) 50 mcg, minimum, stannous chloride, dihydrate (SnCl 2•2H 2 0) 96 mcg, theoretical, tin chloride (stannous, stannic) dihydrate, as stannous chloride, maximum dihydrate 105 mcg, 3.67 mg sodium citrate dihydrate, 5.5 mg anhydrous dextrose and 0.47 mg hydrochloric acid. The pH is adjusted to 7.1 to 7.2 with NaOH prior to lyophilization. 1 Syringe I Each 0.6 mL contains 0.6 mg sodium hypochlorite (NaOCl). NaOH may have been added for pH adjustment. The pH range of this solution is 11 to 13. Total volume: 0.6 mL. Protect from light. 1 Syringe II Each milliliter contains 8.7 mg citric acid monohydrate, 32.5 mg sodium citrate dihydrate and 12 mg anhydrous dextrose. The pH is adjusted to 4.5 to 5.5 with sodium citrate or citric acid as needed. Total volume: 1 mL. 2 Plastic Syringe Plunger Rods 2 Disposable Hypodermic Needles 1 Package Insert 1 Radioassay Information Label Manufactured by: Curium US LLC Maryland Heights, MO 63043 Made in USA A068K0 R02/2025 CURIUM TM image description"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No long term animal studies have been performed to evaluate carcinogenic or mutagenic potential or to determine the effects on male or female fertility."]},"safety":{"boxedWarnings":[],"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Red blood cells","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:42:05.962606+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:42:12.088348+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Red blood cells","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:42:12.407300+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:42:30.020844+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:42:04.780711+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108195/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:42:13.838609+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS None known.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:42:19.598897+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA019981","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:42:04.780734+00:00"}},"_dailymed":{"setId":"9f999b75-8a66-40bf-9352-478850b41225","title":"ULTRATAG RBC (KIT FOR THE PREPARATION OF TECHNETIUM TC 99M RED BLOOD CELLS) KIT [CURIUM US LLC]"},"_scrapedAt":"2026-03-28T01:31:42.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T02:42:30.159950+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"red-blood-cells-blood-pool-imaging","name":"Blood Pool Imaging","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":""},{"id":"red-blood-cells-detection-of-gastrointestinal-","name":"Detection of Gastrointestinal Bleeding","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT00007150","phase":"PHASE2","title":"Treatment of Hemochromatosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2001-01-01","conditions":"Hemochromatosis","enrollment":622},{"nctId":"NCT04404881","phase":"PHASE2","title":"Bevacizumab In Hereditary Hemorrhagic Telangiectasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2020-11-23","conditions":"Hereditary Hemorrhagic Telangiectasia","enrollment":33},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT07492589","phase":"PHASE2","title":"Photo-Acoustic and Ultrasonographic Mammoscope","status":"RECRUITING","sponsor":"Franciscus Gasthuis & Vlietland (Hospital)","startDate":"2026-02-01","conditions":"Benign Breast Lesions, Malignant Breast Tumours","enrollment":180},{"nctId":"NCT03842189","phase":"PHASE2","title":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-05","conditions":"Hemolytic Disease of the Fetus and Newborn","enrollment":25},{"nctId":"NCT01572506","phase":"PHASE1","title":"Mechanisms Accounting for Unexplained Anemia in the Elderly","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2012-03-29","conditions":"Anemia","enrollment":58},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT07231471","phase":"NA","title":"Platelet Rich Plasma for Musculoskeletal Conditions","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-12-29","conditions":"Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Hip","enrollment":10000},{"nctId":"NCT03889834","phase":"NA","title":"Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 ml) in Healthy Volunteers.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-01-25","conditions":"The Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy Volunteers","enrollment":30},{"nctId":"NCT03037164","phase":"PHASE3","title":"INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cerus Corporation","startDate":"2017-05-11","conditions":"Anemia","enrollment":692},{"nctId":"NCT07486531","phase":"","title":"Iron Accumulation in Erythrocytes in Patients","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2024-10-20","conditions":"Beta Thalassemia Major","enrollment":100},{"nctId":"NCT06399822","phase":"NA","title":"Impact of Capillaroscopy on the Management of Undifferentiated Connective Tissue Disease","status":"RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2024-05-22","conditions":"Undifferentiated Connective Tissue Diseases","enrollment":40},{"nctId":"NCT07187401","phase":"PHASE1, PHASE2","title":"A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-02-11","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia","enrollment":24},{"nctId":"NCT06839326","phase":"NA","title":"Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder","status":"COMPLETED","sponsor":"Batman University","startDate":"2024-11-01","conditions":"Temporomandibular Joint Osteoarthritis","enrollment":75},{"nctId":"NCT06331364","phase":"NA","title":"TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): a Stepped-Wedge Cluster Randomized Trial","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-02-27","conditions":"Lower Resp Tract Infection","enrollment":765},{"nctId":"NCT03685721","phase":"","title":"Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-10-11","conditions":"Sickle Cell, PKLR Variants, Adenosine Triphosphate Activities","enrollment":800},{"nctId":"NCT03878706","phase":"","title":"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination","status":"RECRUITING","sponsor":"University of Athens","startDate":"2017-11-03","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06840756","phase":"PHASE4","title":"Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes","status":"RECRUITING","sponsor":"Michelle Zeller","startDate":"2025-09-11","conditions":"Red Blood Cell Transfusions, Sex Differences, Health Services","enrollment":11082},{"nctId":"NCT06734611","phase":"NA","title":"Folic Acid Salt Study (FISFA Zambia)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-05-01","conditions":"Folate Deficiency, Neural Tube Defects","enrollment":250},{"nctId":"NCT07465029","phase":"","title":"A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-02","conditions":"Lower-risk Myelodysplastic Syndromes (TD LR-MDS)","enrollment":1300},{"nctId":"NCT05357560","phase":"PHASE1","title":"A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-07-10","conditions":"Malaria, Plasmodium Falciparum","enrollment":107},{"nctId":"NCT07422480","phase":"PHASE3","title":"A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-04-01","conditions":"Myelodysplastic Syndrome, Anemia","enrollment":300},{"nctId":"NCT00542230","phase":"","title":"Blood Sampling for Research Related to Sickle Cell Disease","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2007-11-07","conditions":"Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia","enrollment":250},{"nctId":"NCT04040023","phase":"NA","title":"Patient Blood Management in Cardiac Surgery","status":"COMPLETED","sponsor":"Clinique Pasteur","startDate":"2019-09-10","conditions":"Surgical Blood Loss","enrollment":900},{"nctId":"NCT06607003","phase":"PHASE1","title":"Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-11-26","conditions":"Malaria","enrollment":300},{"nctId":"NCT04084080","phase":"PHASE3","title":"Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2020-02-26","conditions":"Sickle Cell Disease","enrollment":173},{"nctId":"NCT06875947","phase":"NA","title":"EFFECTS of MORINGA OLEIFERA LEAF POWDERS on HEMATOLOGICAL PROFILES IN PREGNANT WOMEN WITH IRON DEFICIENCY ANAEMIA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fakultas Kedokteran Universitas Padjadjaran","startDate":"2025-05-23","conditions":"Iron Deficiency Anemia of Pregnancy, Pregnancy Complications, Inflammation","enrollment":59},{"nctId":"NCT07446647","phase":"PHASE1","title":"Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion","status":"NOT_YET_RECRUITING","sponsor":"Jose Cancelas","startDate":"2026-03","conditions":"Healthy Volunteer Red Blood Cell Labeling Study; Not Disease Focused","enrollment":20},{"nctId":"NCT07439601","phase":"NA","title":"Long-Term Omega-3 and Omega-3 Index >8%: Effects on Physiological Recovery","status":"NOT_YET_RECRUITING","sponsor":"St. Mary's University, Twickenham","startDate":"2026-02-28","conditions":"Focus on Omega 3 Index on Recovery","enrollment":46},{"nctId":"NCT04171635","phase":"","title":"Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2019-12-16","conditions":"MRI Scans","enrollment":55},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT07436767","phase":"NA","title":"Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Sickle Cell Disease","enrollment":3},{"nctId":"NCT06664853","phase":"PHASE3","title":"Open-Label Extension of EryDex Study IEDAT-04-2022","status":"TERMINATED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-12-11","conditions":"Ataxia Telangiectasia","enrollment":101},{"nctId":"NCT06543368","phase":"NA","title":"Low-Cost Platelet-Rich Plasma for Hemarthropathy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2024-07-23","conditions":"Hemarthrosis, Hemophilia","enrollment":14},{"nctId":"NCT07271758","phase":"NA","title":"PROmega Pilot Study of Clinic-based DHA Blood Screening in Early Pregnancy","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Nutrient Deficiency","enrollment":650},{"nctId":"NCT06313398","phase":"EARLY_PHASE1","title":"Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2024-05-17","conditions":"Sickle Cell Disease, Thalassemia, Hemoglobinopathy","enrollment":100},{"nctId":"NCT07425587","phase":"","title":"Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Bluejay Diagnostics, Inc.","startDate":"2026-04-12","conditions":"Sepsis, Septic Shock","enrollment":450},{"nctId":"NCT05615740","phase":"NA","title":"Prevention of Onset and Transition to an Advanced Form of Diabetic Retinopathy in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2022-05-02","conditions":"Diabetic Retinopathy","enrollment":187},{"nctId":"NCT06979492","phase":"PHASE4","title":"Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Sickle Cell Disease, Pregnancy Related","enrollment":50},{"nctId":"NCT06602804","phase":"NA","title":"Trima Non-DEHP Leukoreduced Red Blood Cell In Vivo Recovery Study","status":"COMPLETED","sponsor":"Terumo BCT","startDate":"2024-08-26","conditions":"Device Validation of In-vivo Performance","enrollment":37},{"nctId":"NCT07416045","phase":"","title":"A Multi-dimensional Evaluation of the Effects of Linear Accelerator X-ray Irradiation on Red Blood Cells","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-28","conditions":"Erythrocyte Destruction","enrollment":20},{"nctId":"NCT07341139","phase":"","title":"Blood Storage Related Mortality and Adverse Effects in Trauma Patients","status":"RECRUITING","sponsor":"Kocaeli City Hospital","startDate":"2026-01-17","conditions":"Transfusion Adverse Reaction, Major Trauma, Blood Product Transfusion for All Conditions","enrollment":300},{"nctId":"NCT04610866","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-12-09","conditions":"Sickle Cell Disease, Hemolytic Anemia","enrollment":15},{"nctId":"NCT06710418","phase":"NA","title":"Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-10-15","conditions":"Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":50},{"nctId":"NCT06168266","phase":"NA","title":"Effects of Eccentric Exercise Training in Patients With COPD","status":"RECRUITING","sponsor":"Fu Jen Catholic University","startDate":"2023-12-13","conditions":"COPD","enrollment":170},{"nctId":"NCT07328191","phase":"NA","title":"Quality of Life-Guided Transfusion in Refractory MDS or AML","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2026-02-09","conditions":"MDS, AML, Adult, Anemia","enrollment":52},{"nctId":"NCT04423367","phase":"PHASE2","title":"Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-09-13","conditions":"Acquired Pure Red Cell Aplasia","enrollment":18},{"nctId":"NCT06909487","phase":"","title":"Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respect to HAS 2014 Recommendations","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-03-25","conditions":"Very Preterm and Extremely Preterm Birth, Anemia, Erythrocyte Transfusion","enrollment":201},{"nctId":"NCT07402005","phase":"","title":"The Correlation of Lewis Antigens With VTE","status":"NOT_YET_RECRUITING","sponsor":"Larissa University Hospital","startDate":"2026-01-19","conditions":"Thromboembolic Disease","enrollment":200},{"nctId":"NCT05582447","phase":"","title":"Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-04-17","conditions":"Cholestasis, Red Cell Membrane and Enzyme Abnormalities","enrollment":40},{"nctId":"NCT02741648","phase":"","title":"RBC Irradiation, Anemia and Gut Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2016-07","conditions":"Anemia, Necrotizing Enterocolitis","enrollment":324},{"nctId":"NCT04419649","phase":"PHASE2","title":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Takeda","startDate":"2020-08-19","conditions":"Myelodysplastic Syndromes, Cytopenia","enrollment":160},{"nctId":"NCT05037760","phase":"PHASE2","title":"A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis","status":"RECRUITING","sponsor":"Takeda","startDate":"2021-12-16","conditions":"Myelofibrosis","enrollment":135},{"nctId":"NCT07380477","phase":"","title":"VentricuLostomy AssoCiaTed InfeCtions (LACTIC): Focus on CSF Lactate and Sampling Site","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-15","conditions":"Acute Brain Injury, Hydrocephalus, External Ventricular Drain","enrollment":148},{"nctId":"NCT07377851","phase":"NA","title":"Carbonic Anhydrase II Responses to Basketball-Specific High-Intensity Interval Training","status":"COMPLETED","sponsor":"Karamanoğlu Mehmetbey University","startDate":"2025-11-01","conditions":"Metabolic Adaptation to High-Intensity Interval Training","enrollment":24},{"nctId":"NCT03814746","phase":"PHASE3","title":"Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-26","conditions":"Sickle Cell Disease (SCD)","enrollment":255},{"nctId":"NCT07376876","phase":"PHASE2","title":"Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-01-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer","enrollment":73},{"nctId":"NCT05612919","phase":"NA","title":"Red Blood Cells From Umbilical Cord for Transfusion of Preterm Infants","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2023-09-13","conditions":"Infant, Extremely Premature, Erythrocyte Transfusion, Umbilical Cord Issue","enrollment":41},{"nctId":"NCT04431999","phase":"PHASE3","title":"Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage","status":"COMPLETED","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2021-12-04","conditions":"Trauma, Acute Hemorrhage, Coagulopathy","enrollment":200},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT06142747","phase":"","title":"Tracking of Red Blood Cells Using Super Resolution Ultrasound in Persons With Healthy or Overuse Injured Tendons","status":"RECRUITING","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2024-02-08","conditions":"Tendinopathy","enrollment":135},{"nctId":"NCT01565434","phase":"NA","title":"Erythrocyte Complement Receptor 1 and Alzheimer Disease","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2012-02","conditions":"Alzheimer Disease","enrollment":200},{"nctId":"NCT07346976","phase":"NA","title":"Investigation Into the Dynamic Variations of End-Tidal Carbon Monoxide Concentration (ETCOc) in Neonates Utilizing Non-Dispersive Infrared Spectroscopy and Its Implications for Jaundice Management","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2025-12-05","conditions":"Neonatal Hyperbilirubinemia","enrollment":100},{"nctId":"NCT07341048","phase":"NA","title":"Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01","conditions":"Polycythemia, Polycythemia Vera (PV)","enrollment":54},{"nctId":"NCT06944067","phase":"","title":"Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2025-06-24","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT06193200","phase":"PHASE3","title":"Evaluate the Neurological Effects of EryDex on Subjects With A-T","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-06-24","conditions":"Ataxia Telangiectasia","enrollment":105},{"nctId":"NCT07329530","phase":"NA","title":"Metabolic and Muscle Profile in ICU Survivors","status":"RECRUITING","sponsor":"Anne-Françoise Rousseau","startDate":"2025-12-01","conditions":"Critical Illness, Major Abdominal Surgeries","enrollment":100},{"nctId":"NCT05071079","phase":"NA","title":"A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2022-05-23","conditions":"Plasmodium Vivax Infection","enrollment":48},{"nctId":"NCT04591574","phase":"NA","title":"ABC - A Post Intensive Care Anaemia Management Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-09-01","conditions":"Anemia Acute, Fatigue, Physical Disability","enrollment":346},{"nctId":"NCT07329231","phase":"NA","title":"Quinoa Improves Glycolipid Metabolism and Glucose Fluctuation Based on β-Cell Function in Early-stage Type 2 Diabetes","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-01-10","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":60},{"nctId":"NCT07326670","phase":"","title":"Effects of Spinal vs General Anesthesia on Systemic Inflammation in PCNL","status":"RECRUITING","sponsor":"Elazıg Fethi Sekin Sehir Hastanesi","startDate":"2025-10-15","conditions":"Anesthesia Techniques, Percutaneous Nephrolithotomy, Systemic Inflammation","enrollment":90},{"nctId":"NCT05100342","phase":"","title":"Prospective Validation of a Points Score System Predicting 30-day Survival","status":"RECRUITING","sponsor":"Indiana University","startDate":"2022-09-12","conditions":"Metastatic Cancer","enrollment":114},{"nctId":"NCT01174108","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-12-10","conditions":"Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)","enrollment":120},{"nctId":"NCT05545930","phase":"NA","title":"Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell)","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-09-20","conditions":"Blood Recovery","enrollment":20},{"nctId":"NCT06721455","phase":"","title":"Modeling Blood Management and Hemolytic Risk in Pediatric Heart Surgery","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-08-01","conditions":"Heart Surgery, Blood Transfusion, Hemolysis","enrollment":50},{"nctId":"NCT06743113","phase":"NA","title":"Hypoxic Red Blood Cells in Sickle Cell Anemia","status":"NOT_YET_RECRUITING","sponsor":"Hemanext","startDate":"2026-03","conditions":"Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children","enrollment":48},{"nctId":"NCT06685848","phase":"NA","title":"Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion","status":"RECRUITING","sponsor":"Hemanext","startDate":"2024-11-29","conditions":"Hematologic Neoplasms","enrollment":24},{"nctId":"NCT05451940","phase":"PHASE1, PHASE2","title":"Hydroxyurea and EPO in Sickle Cell Disease","status":"COMPLETED","sponsor":"Julia Xu","startDate":"2023-05-25","conditions":"Anemia, Sickle Cell, Sickle Cell Disease","enrollment":17},{"nctId":"NCT04143724","phase":"PHASE2","title":"Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia","status":"RECRUITING","sponsor":"Celgene","startDate":"2019-11-07","conditions":"Beta-Thalassemia","enrollment":99},{"nctId":"NCT07320391","phase":"NA","title":"Ozonated Gel and Titanium Platelet-rich Fibrin (on Palatal Wound Healing","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-05-01","conditions":"Palatal Lesion","enrollment":39},{"nctId":"NCT07092683","phase":"","title":"Mediation Analysis in Cardiac Surgery","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-01","conditions":"Anemia, Cardiac Surgery, Transfusion","enrollment":13683},{"nctId":"NCT07313878","phase":"NA","title":"Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy","status":"RECRUITING","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2025-11-19","conditions":"Acute Lymphoblastic Leukaemias (ALL), Long Term Follow-Up","enrollment":30},{"nctId":"NCT05470816","phase":"PHASE3","title":"Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayside Health","startDate":"2022-11-01","conditions":"Surgical Site Infection, Dementia, Cognition","enrollment":826},{"nctId":"NCT06060639","phase":"NA","title":"Variation of Echocardiographic Parameters After Red Blood Cell Transfusion in Emergency Department Anemic Patients","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-11-09","conditions":"Anemia, Age Problem, Ultrasonography","enrollment":116},{"nctId":"NCT07307872","phase":"","title":"A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease","status":"COMPLETED","sponsor":"Amoneta Diagnostics SAS","startDate":"2017-03-23","conditions":"Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia","enrollment":150},{"nctId":"NCT06457295","phase":"","title":"Impact of Diabetes Mellitus on Retinal Microvasculature in Patients Without Clinical Retinopathy Using Optical Coherence Tomography Angiography","status":"COMPLETED","sponsor":"Sohag University","startDate":"2024-12-20","conditions":"Diabetic Retinopathy, DR","enrollment":200},{"nctId":"NCT02352181","phase":"NA","title":"Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment.","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-12","conditions":"Liver Transplantation","enrollment":82},{"nctId":"NCT04983654","phase":"NA","title":"Functional and Mechanistic Characterization of Limb Ulcers in Patients With Sickle Cell Disease","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2022-02-09","conditions":"Ulcer, Anemia, Sickle Cell Disease","enrollment":70},{"nctId":"NCT07055503","phase":"","title":"Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia Patients","status":"ENROLLING_BY_INVITATION","sponsor":"University Research Institute for the Study of Genetic & Malignant Disorders in Childhood","startDate":"2025-11-20","conditions":"Transfusion-dependent Beta-Thalassemia, Blood Transfusion","enrollment":30},{"nctId":"NCT07287371","phase":"PHASE4","title":"Sucrosomial Vs Intravenous Iron for Preoperative Anemia","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2025-12-31","conditions":"Anemia, Iron Deficiency Anemia","enrollment":75},{"nctId":"NCT05348915","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-03-29","conditions":"Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease","enrollment":242},{"nctId":"NCT04987489","phase":"PHASE2","title":"A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease","status":"COMPLETED","sponsor":"Forma Therapeutics, Inc.","startDate":"2022-03-28","conditions":"Sickle Cell Disease, Thalassemia","enrollment":53},{"nctId":"NCT02750150","phase":"PHASE3","title":"Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2013-07-09","conditions":"Trauma, Coagulopathy","enrollment":42},{"nctId":"NCT07121140","phase":"NA","title":"Home Blood Transfusions","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-06-03","conditions":"Hematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT04137692","phase":"NA","title":"Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome","status":"SUSPENDED","sponsor":"Weill Medical College of Cornell University","startDate":"2027-09","conditions":"Glucose Transporter Type 1 Deficiency Syndrome, GLUT1DS1","enrollment":12},{"nctId":"NCT05979207","phase":"PHASE1","title":"Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2023-08-01","conditions":"Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome","enrollment":12},{"nctId":"NCT06485960","phase":"","title":"Validation of the Experience Sampling Dietary Assessment Method","status":"RECRUITING","sponsor":"KU Leuven","startDate":"2025-10-09","conditions":"Validation Study","enrollment":115},{"nctId":"NCT06285604","phase":"","title":"Effect Evaluation of Different Blood Products Infusion on Neonatal Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2024-09-10","conditions":"Neonatal Anemia","enrollment":200},{"nctId":"NCT07269899","phase":"PHASE1","title":"A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-25","conditions":"Solid Tumor Cancer, Cancer","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2108195"},"_approvalHistory":[],"publicationCount":56177,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RBCs"],"phase":"marketed","status":"active","brandName":"Red blood cells","genericName":"Red blood cells","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T02:42:30.159950+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}